BE HEARD long-term data show bimekizumab (Bimzelx) IL‑17A/F reduces hidradenitis suppurativa draining tunnels while boosting IHS4 and quality of life.
Thrasyvoulos Tzellos, MD, PhD
Advertisement
Thrasyvoulos Tzellos, MD, PhD, is a dermatologist in Norway at Nordland Hospital Trust, who specializes in hidradenitis suppurativa.
Articles by Thrasyvoulos Tzellos, MD, PhD
Thrasyvoulos Tzellos, MD, PhD, explains HS’s progressive toll and how UCB’s BE HEARD bimekizumab data shows durable tunnel reduction and lasting disease improvement.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Dermatology Times
1
Dermalogica Enters Medical Aesthetics with FDA-Cleared Microneedling PRO Pen
2
Social Media Mythbusters: Hypochlorous Acid Sprays
3
Quoin Submits First-Ever IND Application for Peeling Skin Syndrome Therapy
4
Topical GX-03 Hits 92.6% EASI-50 at Week 4 in Phase 2 AD Interim
5